Valneva SE (VALN) Operating Expenses (2021 - 2026)
Valneva SE's (VALN) quarterly Operating Expenses came in at -$27.4 million in Q1 2026, down 8.82% year-on-year from -$30.0 million in Q1 2025, and down 111.1% quarter-over-quarter from $246.6 million in Q4 2025.
Valneva SE (VALN) Operating Expenses (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Operating Expenses across 6 years of filings, most recently posting -$27.4 million for Q1 2026.
- Operating Expenses for Q1 2026 came in at -$27.4 million, down 8.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $143.9 million (up 15.9% YoY), and the FY2025 annual result was $142.7 million, up 14.27% from the prior year.
- Operating Expenses came in at -$27.4 million for Q1 2026 at Valneva SE, down from $246.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $246.6 million in Q4 2025 to a low of -$44.2 million in Q2 2022.
- The 5-year median for Operating Expenses is -$27.4 million (2026), against an average of $28.3 million.
- Peak annual rise in Operating Expenses reached 46.65% in 2022, while the deepest fall reached 42.68% in 2022.
- Valneva SE's Operating Expenses stood at $242.5 million in 2022, then slipped by 22.88% to $187.0 million in 2023, then increased by 13.17% to $211.6 million in 2024, then gained by 16.56% to $246.6 million in 2025, then plunged by 111.1% to -$27.4 million in 2026.
- The last three Operating Expenses figures came in at -$27.4 million (Q1 2026), $246.6 million (Q4 2025), and -$44.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 15.76 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -67.40 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -27.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.38 Mn |
| Dec 31, 2025 | 246.64 Mn |
| Sep 30, 2025 | -44.16 Mn |
| Jun 30, 2025 | -31.19 Mn |
| Mar 31, 2025 | -25.16 Mn |
| Dec 31, 2024 | 211.60 Mn |
| Sep 30, 2024 | -31.40 Mn |
| Jun 30, 2024 | -30.88 Mn |
| Mar 31, 2024 | -26.94 Mn |
| Dec 31, 2023 | 186.98 Mn |
| Sep 30, 2023 | -30.93 Mn |
| Jun 30, 2023 | -26.98 Mn |
| Mar 31, 2023 | -25.87 Mn |
| Dec 31, 2022 | 242.46 Mn |
| Sep 30, 2022 | -30.99 Mn |
| Jun 30, 2022 | -44.23 Mn |
| Mar 31, 2022 | -29.70 Mn |
| Dec 31, 2021 | 423.03 Mn |
| Sep 30, 2021 | -58.09 Mn |
| Jun 30, 2021 | -74.54 Mn |